🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,522 results for “solution” Clear

  1. Vyvgart 20 mg/mL concentrate for solution for infusion

    argenx

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  2. Wegovy 0.25 mg FlexTouch solution for injection in pre-filled pen, Wegovy 0.5 mg FlexTouch solution for injection in pre-filled pen, Wegovy 1.7 mg FlexTouch solution for injection in pre-filled pen, Wegovy 2.4 mg FlexTouch solution for injection in pre-filled pen, KAI-9531, Wegovy 1 mg FlexTouch solution for injection in pre-filled pen, KAI-9531, KAI-9531

    Kailera Therapeutics

    Obesity

    phase 3 small molecule active

    1 trial

  3. Wegovy 2.4 mg FlexTouch solution for injection in pre-filled pen, Wegovy 0.25 mg FlexTouch solution for injection in pre-filled pen, Placebo Semaglutide, Wegovy 0.5 mg FlexTouch solution for injection in pre-filled pen, Placebo NNC0487 0111 B, Wegovy 1 mg FlexTouch solution for injection in pre-filled pen, Wegovy 1.7 mg FlexTouch solution for injection in pre-filled pen, NNC0487-0111 B 10144, NNC0487-0111 B 10145, NNC0487-0111 B 10146, NNC0487-0111 B 10141, NNC0487-0111 B 10142, NNC0487-0111 B 10143

    NovoThirteen

    Participants with overweight or obesity, and type 2 diabetes

    phase 3 small molecule active

    1 trial

  4. Wegovy 2.4 mg solution for injection in pre-filled pen, Rybelsus 14 mg tablets, Clopidogrel Medreg 75 mg filmom obalené tablety, Wegovy 0.25 mg solution for injection in pre-filled pen, Wegovy 0.5 mg solution for injection in pre-filled pen, Wegovy 1 mg solution for injection in pre-filled pen, Rybelsus 7 mg tablets, Wegovy 1.7 mg solution for injection in pre-filled pen, Acetylsalicylic acid Krka 100 mg enterotabletter, Rybelsus 3 mg tablets

    Istituto Gentili S.r.l.

    Diabetes Mellitus, Cardiovascular disease, Overweight (BMI ≥27 kg/m²), Obesity (BMI≥30kg/m2)

    phase 3 small molecule active

    1 trial

  5. XELJANZ 1 mg/mL oral solution, XELJANZ 1 mg/mL oral solution, XELJANZ 1 mg/mL oral solution, Tofacitinib citrate, Tofacitinib citrate, XELJANZ 1 mg/mL oral solution

    Pfizer Australia Pty Ltd

    Ulcerative Colitis (UC)

    phase 3 small molecule active

    1 trial

  6. XEOMIN 100 unités, poudre pour solution injectable

    Pari Pharma GmbH

    PANCREATIC FISTULA

    phase 3 small molecule active

    1 trial

  7. XEOMIN 200 jednotek prášek pro injekční roztok, XEOMIN, 200 jednostek, proszek do sporządzania roztworu do wstrzykiwań, XEOMEEN 200 eenheden poeder voor oplossing voor injectie, XEOMIN 200 egység por oldatos injekcióhoz, XEOMIN 200 jednotiek prášok na injekčný roztok, XEOMIN 200 unidades polvo para solución inyectable, XEOMEEN 200 unités poudre pour solution injectable, XEOMIN 200 Einheiten Pulver zur Herstellung einer Injektionslösung, XEOMIN 200 unités, poudre pour solution injectable, XEOMIN, 200 unità,

    Merz Pharmaceuticals GmbH

    Lower limb spasticity

    phase 3 small molecule active

    1 trial

  8. XEOMIN 200 unités, poudre pour solution injectable, Placebo of Xeomin 200 U

    Pari Pharma GmbH

    Adult patients with indication for conventional cardiac surgery (CABG, aortic replacement, or ascending aorta surgery)

    phase 3 small molecule active

    1 trial

  9. Xofigo 1100 kBq/mL solution for injection

    Ningbo Cancer Hospital

    metastatic Castration-Resistant Prostate Cancer (mCRPC)

    phase 3 small molecule active

    1 trial

  10. Xolair 150 mg solution for injection in pre-filled syringe, Placebo, solution for injection in pre-filled syringe, BP11

    CuraTeQ Biologics s.r.o

    Chronic Urticaria

    phase 3 small molecule active

    1 trial

  11. Xtandi - 40 mg soft capsules, Xofigo 1100 kBq/mL solution for injection

    Ningbo Cancer Hospital

    Castration resistant prostate cancer patients metastatic to bone.

    phase 3 small molecule active

    1 trial

  12. Xyrem (sodium oxybate) oral solution

    Jazz Pharmaceuticals Ireland Limited

    Narcolepsy

    phase 3 small molecule completed

    1 trial

  13. YERVOY 5 mg/ml concentrate for solution for infusion, OPDIVO 10 mg/mL concentrate for solution for infusion.

    CERO THERAPEUTICS HOLDINGS, INC.

    Non small cell lung cancer

    phase 3 small molecule active

    1 trial

  14. YERVOY 5 mg/ml concentrate for solution for infusion, OPDIVO 10 mg/mL concentrate for solution for infusion., YERVOY 5 mg/ml concentrate for solution for infusion, Irinotecan Bendalis 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, FLUOROURACIL, OPDIVO 10 mg/mL concentrate for solution for infusion., Avastin 25 mg/ml concentrate for solution for infusion, DISODIUM FOLINATE

    Bristol-Myers Squibb Australia Pty Ltd

    Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient Metastatic Colorectal Cancer (dMMR)

    phase 3 small molecule active

    1 trial

  15. YESCARTA 0.4 – 2 x 10e8 cells dispersion for infusion, Revlimid 20 mg hard capsules, Bendamustine 100mg Powder for Concentrate for Solution for Infusion, Vincristine Sulfate 1 mg/ml Solution for Injection or Infusion, Doxorubicin Teva 2 mg/ml Concentrate for Solution for Infusion, Endoxana Injection 1000 mg Powder for Solution for Injection, Prednisolone 5 mg Soluble Tablets, MabThera 500 mg concentrate for solution for infusion

    Lacuna Pharma Pty Ltd

    Relapsed/Refractory Follicular Lymphoma

    phase 3 small molecule active

    1 trial

  16. Yorvipath 420 micrograms/1.4 mL solution for injection in pre‑filled pen, Yorvipath 168 micrograms/0.56 mL solution for injection in pre-filled pen, Yorvipath 294 micrograms/0.98 mL solution for injection in pre‑filled pen

    Ascendis Pharma Bone Diseases A/S

    Chronic hypoparathyroidism

    phase 3 small molecule active

    1 trial

  17. Zanubrutinib, Bendamustin Hikma 2,5 mg/ml Pulver für ein Konzentrat zur Herstellung einer Infusionslösung, MabThera 100 mg concentrate for solution for infusion, Bendamustin Kabi 2,5 mg/ml Pulver für ein Konzentrat zur Herstellung einer Infusionslösung, MabThera 500 mg concentrate for solution for infusion

    BEONE MEDICINES AUS PTY LTD

    Mantle Cell Lymphoma

    phase 3 small molecule active

    1 trial

  18. Zelvina 15 mg hard capsules, Zelvina 5 mg hard capsules, ELRANATAMAB, Zelvina 10 mg hard capsules, Privigen 100 mg/ml solution for infusion

    Pfizer Australia Pty Ltd

    Multiple Myeloma

    phase 3 small molecule active

    1 trial

  19. Zelvina 25 mg hard capsules, Dexamethasone 0.5mg Tablets, Zelvina 15 mg hard capsules, ELRANATAMAB, Privigen 100 mg/ml solution for infusion, Zelvina 2.5 mg hard capsules, Zelvina 10 mg hard capsules, VELCADE 3.5 mg powder for solution for injection, Nodexon 20 mg tabletid, DARZALEX 1800 mg solution for injection, Nodexon 20 mg tabletės, Nodexon 20 mg tabletes, Nodexon 20 mg tabletės, Dexamethasone 4 mg tablets, Zelvina 5 mg hard capsules

    Pfizer Australia Pty Ltd

    Multiple myeloma

    phase 3 small molecule active

    1 trial

  20. Zelvina 25 mg hard capsules, Zelvina 10 mg hard capsules, Zelvina 15 mg hard capsules, Zelvina 5 mg hard capsules, Zelvina 20 mg hard capsules, MINJUVI 200 mg powder for concentrate for solution for infusion

    Incyte

    Diffuse large B-cell lymphoma (DLBCL)

    phase 3 small molecule active

    1 trial

  21. Zelvina 5 mg hard capsules, Dexamethasone Tablets BP 2.0mg, Fortecortin® 2 mg Tabletten, Revlimid 25 mg hard capsules, Zelvina 10 mg hard capsules, Revlimid 5 mg hard capsules, Dexamethason 8 mg GALEN® Tabletten, Revlimid 10 mg hard capsules, Dexamethason 8 mg JENAPHARM®, Zelvina 25 mg hard capsules, DARZALEX 1800 mg solution for injection

    GlaxoSmithKline

    Multiple myeloma

    phase 3 small molecule active

    1 trial

  22. Zilbrysq 23 mg solution for injection in pre-filled syringe, Zilucoplan sodium, -, Zilbrysq 16.6 mg solution for injection in pre-filled syringe, Zilbrysq 32.4 mg solution for injection in pre-filled syringe

    Lacuna Pharma Pty Ltd

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  23. Zilbrysq 32.4 mg solution for injection in pre-filled syringe, Zilbrysq 23 mg solution for injection in pre-filled syringe, Zilbrysq 16.6 mg solution for injection in pre-filled syringe

    Lacuna Pharma Pty Ltd

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  24. Zilbrysq 32.4 mg solution for injection in pre-filled syringe, Zilbrysq 23 mg solution for injection in pre-filled syringe, Zilucoplan sodium, -, Zilbrysq 16.6 mg solution for injection in pre-filled syringe

    Lacuna Pharma Pty Ltd

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources